Some studies have shown that IL‐17A can enhance the expression of type 2 cytokines and eosinophil infiltration in ECRS or NP mouse model, which might provide a new option for the treatment of CRS with biologics.135, 136. This evidence concerns the gene IL17A and congenital rubella syndrome.